Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo- and Active-controlled Parallel-group Multi-center Phase III Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines

NCT06499688 is registered in ClinicalTrials.gov with Chongqing Claruvis Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT06499688
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06499688 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo- and Active-controlled Parallel-group Multi-center Phase III Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines
Lead sponsor
Chongqing Claruvis Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
December 28, 2023
Completion date
May 31, 2024
Enrollment
529 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

moderate to severe glabellar lines